Daily21h
USFDA accepts GSK depemokimab applications for review for asthma, chronic rhinosinusitis
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License ...
Pharmabiz18h
Positive results from the Tezspire phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps
Positive results from the Tezspire phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps: Cambridge, UK Tuesday, March 4, 2025, ...
Pharmabiz21h
Roche announces positive results from phase III OUtMATCH study of Xolair for the treatment of one or more food allergies
Roche announces positive results from phase III OUtMATCH study of Xolair for the treatment of one or more food allergies: Basel Tuesday, March 4, 2025, 12:00 Hrs [IST] Roche annou ...